Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gert Van Assche

Showing results (181-190 of 287) with videos related to

Pageof 29
Sort By:
Journal of Clinical Gastroenterology|December 3, 2019
Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease PatientsIris Detrez, Debby Thomas, Kristel Van Steen, et al.
Gut|April 17, 2015
Immunogenicity to infliximab is associated with HLA-DRB1Thomas Billiet, Niels Vande Casteele, Thomas Van Stappen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2014
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remissionKonstantinos Papamichael, Niels Vande Casteele, Ann Gils, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Inflammatory Bowel Diseases|August 11, 2011
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyFabian Schnitzler, Herma Fidder, Marc Ferrante, et al.
Gut|September 28, 2011
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trialGert Van Assche, Séverine Vermeire, Vera Ballet, et al.
Inflammatory Bowel Diseases|May 30, 2014
Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitisMagali de Bruyn, Ingrid Arijs, Willem-Jan Wollants, et al.
Gastroenterology|October 13, 2009
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert, Liesbeth Moortgat, Gert Van Assche, et al.
Frontiers in Medicine|November 5, 2019
Inflammatory Bowel Disease (IBD)-A Textbook Case for Multi-Centric Banking of Human Biological MaterialsIsabelle Cleynen, Loes Linsen, Sare Verstockt, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
Pageof 29

Showing results (181-190 of 287) with videos related to

Sort By:
Pageof 29
Journal of Clinical Gastroenterology|December 3, 2019
Successful Infliximab Treatment is Associated With Reversal of Clotting Abnormalities in Inflammatory Bowel Disease PatientsIris Detrez, Debby Thomas, Kristel Van Steen, et al.
Gut|April 17, 2015
Immunogenicity to infliximab is associated with HLA-DRB1Thomas Billiet, Niels Vande Casteele, Thomas Van Stappen, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|December 6, 2014
Long-term outcome of patients with Crohn's disease who discontinued infliximab therapy upon clinical remissionKonstantinos Papamichael, Niels Vande Casteele, Ann Gils, et al.
Clinical Gastroenterology and Hepatology : the Official Clinical Practice Journal of the American Gastroenterological Association|April 29, 2018
Evidence to Support Monitoring of Vedolizumab Trough Concentrations in Patients With Inflammatory Bowel DiseasesErwin Dreesen, Bram Verstockt, Sumin Bian, et al.
Inflammatory Bowel Diseases|August 11, 2011
Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapyFabian Schnitzler, Herma Fidder, Marc Ferrante, et al.
Gut|September 28, 2011
Switch to adalimumab in patients with Crohn's disease controlled by maintenance infliximab: prospective randomised SWITCH trialGert Van Assche, Séverine Vermeire, Vera Ballet, et al.
Inflammatory Bowel Diseases|May 30, 2014
Neutrophil gelatinase B-associated lipocalin and matrix metalloproteinase-9 complex as a surrogate serum marker of mucosal healing in ulcerative colitisMagali de Bruyn, Ingrid Arijs, Willem-Jan Wollants, et al.
Gastroenterology|October 13, 2009
Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's diseaseFilip Baert, Liesbeth Moortgat, Gert Van Assche, et al.
Frontiers in Medicine|November 5, 2019
Inflammatory Bowel Disease (IBD)-A Textbook Case for Multi-Centric Banking of Human Biological MaterialsIsabelle Cleynen, Loes Linsen, Sare Verstockt, et al.
Journal of Crohn'S & Colitis|February 5, 2019
Ustekinumab Exposure-outcome Analysis in Crohn's Disease Only in Part Explains Limited Endoscopic Remission RatesBram Verstockt, Erwin Dreesen, Maja Noman, et al.
Pageof 29